Focuses on clinical features, laboratory diagnosis, prognostic factors and therapeutic
management of patients with acquired hemophilia. Association of acquired hemophilia with …

Normal pregnancy is associated with profound alterations in the coagulation and fibrinolytic
systems. While these physiological procoagulant changes are aimed to minimise …

Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of
bleeding in patients with haemophilia A or B and inhibitors. Over the past ten years, it has …

The development of factor VIII autoantibodies is a rare but severe complication of
pregnancy. Although the natural history of postpartum acquired hemophilia A is usually …

Abstract Background About 1%–5% of acquired haemophilia A cases affect mothers in the
postpartum setting. Aims This study delineates the characteristics of this disease, specific to …

We have assessed the proficiency of diagnostic haemostasis facilities to correctly identify
coagulation factor abnormalities and inhibitors. Forty-two laboratories participating in the …

Abstract Development of inhibitors is perhaps the most serious complication of factor VIII
(FVIII) replacement therapy, which can practically preclude efficient clinical management of …

Aims We previously reported the ability of diagnostic haemostasis facilities to identify
coagulation factor abnormalities and inhibitors, through a large multi-centre study conducted …

Acquired haemophilia due to antibodies directed against coagulation factor VIII is a well‐
recognized cause of severe haemorrhage in adults but an uncommon cause of bleeding in …